Search Results - "Osiyemi, O"

Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen by Crauwels, HM, Osiyemi, O, Zorrilla, C, Bicer, C, Brown, K

“…Objectives The aim of the study was to evaluate darunavir and cobicistat pharmacokinetics in pregnant women with HIV‐1 infection. Methods This phase 3b,…”
Get full text

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials by Hagins, D, Orkin, C, Daar, ES, Mills, A, Brinson, C, DeJesus, E, Post, FA, Morales‐Ramirez, J, Thompson, M, Osiyemi, O, Rashbaum, B, Stellbrink, H‐J, Martorell, C, Liu, H, Liu, Y‐P, Porter, D, Collins, SE, SenGupta, D, Das, M

“…Objectives The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV‐1‐infected adults was approved…”
Get full text

Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women by Crauwels, HM, Kakuda, TN, Ryan, B, Zorrilla, C, Osiyemi, OO, Yasin, S, Brown, K, Verboven, P, Hillewaert, V, Baugh, B

“…Objectives HIV antiretroviral therapy during pregnancy is recommended to reduce the risk of mother‐to‐child transmission and for maternal care. Physiological…”
Get full text

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily by Zorrilla, CD, Wright, R, Osiyemi, OO, Yasin, S, Baugh, B, Brown, K, Coate, B, Verboven, P, Mrus, J, Falcon, R, Kakuda, TN

“…Objectives Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother‐to‐child transmission of HIV and for maternal care management…”
Get full text

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial by Orkin, Chloe, Molina, Jean-Michel, Negredo, Eugenia, Arribas, José R, Eron, Joseph J, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Vanveggel, Simon, Ajana, F, Arribas, JR, Bailey, J, Benson, P, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, de Vente, J, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Fehr, J, Felizarta, F, Flamholc, L, Florence, E, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girard, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Huhn, G, Iribarren, JA, Jain, M, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Orkin, C, Osiyemi, O, Perez-Valero, I, Pineda, JA, Podzamczer, D, Portilla Sogorb, J, Post, F, Prelutsky, D, Pulido, F, Rachlis, A, Raffi, F, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Gil, I Santos, Scarsella, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Ustianowski, A, Van Wijngaerden, E, Vandercam, B, Walmsley, S, Wilkin, A, Witor, A, Yazdanpanah, Y

“…Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of…”
Get full text

Antibiotic susceptibilities of bacteria isolated within the oral flora of Florida blacktip sharks: guidance for empiric antibiotic therapy by Unger, Nathan R, Ritter, Erich, Borrego, Robert, Goodman, Jay, Osiyemi, Olayemi O

“…Sharks possess a variety of pathogenic bacteria in their oral cavity that may potentially be transferred into humans during a bite. The aim of the presented…”
Get full text

Safety and exposure of once‐daily ritonavir‐boosted atazanavir in HIV‐infected pregnant women by Conradie, F, Zorrilla, C, Josipovic, D, Botes, M, Osiyemi, O, Vandeloise, E, Eley, T, Child, M, Bertz, R, Hu, W, Wirtz, V, McGrath, D

“…Objective There are limited antiretroviral options for use in the treatment of HIV infection during pregnancy. The purpose of this study was to assess the…”
Get full text

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults by DeJesus, Edwin, Lalezari, Jacob P, Osiyemi, Olayemi O, Ruane, Peter J, Ryan, Robert, Kakuda, Thomas N, Witek, James

“…A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir…”
Get more information

Cerebral phaeohyphomycosis due to a novel species : Report of a case and review of the literature by OSIYEMI, Olayemi O, DOWDY, Lorraine M, MALLON, Stephen M, CLEARY, Timothy

“…Cerebral phaeohyphomycosis is a rare disease caused by dematiaceous (darkly pigmented) fungi. Cladophialophora species are highly neurotropic, and…”
Get full text

Tensile failure of adhesively bonded CFRP composite scarf joints by Kumar, S.B., Sridhar, I., Sivashanker, S., Osiyemi, S.O., Bag, A.

“…Adhesively bonded scarf joints, comprising unidirectional carbon fibre-reinforced epoxy adherends and AF-163-2 film adhesive of 0.15 mm thick, are tested under…”
Get full text

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial by Mills, Anthony M, Rizzardini, Giuliano, Ramgopal, Moti N, Osiyemi, Olayemi O, Bogner, Johannes R, Hagins, Debbie P, Paredes, Roger, Reynes, Jacques, Rockstroh, Jürgen K, Carr, Andrew, Su, Feng-Hsiu, Klopfer, Stephanie O, Eves, Karen, Plank, Rebeca M, Correll, Todd, Fox, Michelle C

“…Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for…”
Get full text

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients by Gottlieb, Robert L, Vaca, Carlos E, Paredes, Roger, Mera, Jorge, Webb, Brandon J, Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Nielsen, Bibi U, Brown, Michael, Hidalgo, Ausberto, Sachdeva, Yessica, Mittal, Shilpi, Osiyemi, Olayemi, Skarbinski, Jacek, Juneja, Kavita, Hyland, Robert H, Osinusi, Anu, Chen, Shuguang, Camus, Gregory, Abdelghany, Mazin, Davies, Santosh, Behenna-Renton, Nicole, Duff, Frank, Marty, Francisco M, Katz, Morgan J, Ginde, Adit A, Brown, Samuel M, Schiffer, Joshua T, Hill, Joshua A

“…Among nonhospitalized patients with Covid-19–related symptoms that began less than a week previously, a 3-day course of remdesivir resulted in an 87% lower…”
Get full text

Mode-I adhesive fracture energy measurement with modified single-lap joint test geometry by Kumar, S. B., Sridhar, I., Sivashanker, S., Osiyemi, S. O.

“…The adhesive fracture energy or fracture toughness of adhesively-bonded joints comprising carbon-fiber-reinforced polymer composite substrates and three…”
Get full text

In vitro antimicrobial activity of crude ethanol extracts and fractions of Terminalia catappa and Vitex doniana by Abiodun, O O, Sood, S, Osiyemi, O A, Agnihotri, V K, Gulati, A, Ajaiyeoba, E O, Singh, B

“…The spread of microorganisms resistant to some antimicrobial agents necessitates the need to search for novel and effective antimicrobial agents. In this…”
Get more information

Uniaxial compressive failure of unidirectional composites with small imperfections by SIVASHANKER, S, OSIYEMI, S. O

“…In this investigation, it was observed that the presence of a small defect such as a tiny hole can significantly reduce the compressive strength of composites…”
Get full text

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 by Eron, Joseph J., Orkin, Chloe, Cunningham, Douglas, Pulido, Federico, Post, Frank A., De Wit, Stéphane, Lathouwers, Erkki, Jezorwski, John, Petrovic, Romana, Brown, Kimberley, Van Landuyt, Erika, Opsomer, Magda, De Wit, S., Florence, E., Van Wijngaerden, E., Vandercam, B., Brunetta, J., Klein, M., Murphy, D., Rachlis, A., Shafran, S., Walmsley, S., Ajana, F., Cotte, L., Girardy, P.-M., Katlama, C., Molina, J.-M., Poizot-Martin, I., Raffi, F., Rey, D., Reynes, J., Teicher, E., Yazdanpanah, Y., Gasiorowski, J., Piekarska, A., Witor, A., Arribas, J.R., Perez-Valero, I., Casado, J., Gatell, J.M., Gutierrez, F., Galindo, M.J., Gutierrez, M.D.M., Iribarren, J.A., Knobel, H., Negredo, E., Pineda, J.A., Podzamczer, D., Sogorb, J.Portilla, Pulido, F., Ricart, C., Rivero, A., Santos Gil, I., Blaxhult, A., Flamholc, L., Gisslèn, M., Thalme, A., Rauch, A., Stoeckle, M., Gazzard, B.G., Post, F., Ustianowski, A., Bailey, J., Benson, P., Bhatti, L., Brar, I., Bredeek, U.F., Brinson, C., Dietz, C., Dretler, R., Felizarta, F., Fichtenbaum, C., Gallant, J., Gathe, J., Hagins, D., Henn, S., Henry, W.K., Huhn, G., Lucasti, C., Martorell, C., McDonald, C., Mills, A., Morales-Ramirez, J., Mounzer, K., Nahass, R., Olivet, H., Prelutsky, D., Ramgopal, M., Rashbaum, B., Richmond, G., Ruane, P., Scarsella, A., Scribner, A., Shalit, P., Shamblaw, D., Slim, J., Tashima, K., Ward, D., Wilkin, A., de Vente, J.

“…Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917)…”
Get full text

Mechanical performance of carbon-fibre- and glass-fibre-reinforced epoxy I-beams: I. Mechanical behaviour by Gilchrist, M.D., Kinloch, A.J., Matthews, F.L., Osiyemi, S.O.

“…This paper is the first in a series which detail the mechanical behaviour, finite element predictions and fractographic observations of the failure of…”
Get full text

Comparison of viral replication for the 2-drug regimen in the TANGO study through week 96 by Wang, R, Wright, J, George, N, Ait-Khaled, M, Lutz, T, Osiyemi, O, Gorgolas, M, Leone, P, Wynne, B, van Wyk, J, Underwood, M

Get full text

Comparison of viral replication for the 2-drug regimen by Wang, R, Wynne, B, Osiyemi, O, Underwood, M, Wright, J, Leone, P, Gorgolas, M, van Wyk, J, Ait-Khaled, M, Lutz, T, George, N

Get full text

Compressive failure of a unidirectional carbon-epoxy composite at high strain rates by SIVASHANKER, S, OSIYEMI, S. O, BAG, Asim

Get full text